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Abstract Naloxone, an opioid antagonist, has been widely used to save lives from opioid overdose, a leading cause for
death in the opioid epidemic. However, naloxone has short brain retention ability, which limits its therapeutic efficacy.
Developing better opioid antagonists is critical in combating the opioid epidemic. Instead of exhaustively searching in
a huge chemical space for better opioid antagonists, we adopt reinforcement learning which allows efficient gradient-
based search towards molecules with desired physicochemical and/or biological properties. Specifically, we implement
a deep reinforcement learning framework to discover potential lead compounds as better opioid antagonists with
enhanced brain retention ability. A customized multi-objective reward function is designed to bias the generation
towards molecules with both sufficient opioid antagonistic effect and enhanced brain retention ability. Thorough
evaluation demonstrates that with this framework, we are able to identify valid, novel and feasible molecules with
multiple desired properties, which has high potential in drug discovery.
1 Introduction
Over the last 20 years, there is a dramatic rise in the use and misuse of opioids in the United States, including misuse
of prescription opioids, resurgence in heroin use and increase in abuse of illicit synthetic opioids such as fentanyl,
which led to the current opioid epidemic and caused a rising number of overdose deaths1. According to the Centers
for Disease Control and Prevention, the rate of opioid overdose deaths keeps rising from 1999 to 2018, posing a major
threat to public health2. Opioid overdose happens when an excessive amount of opioid agonists work on the µ-opioid
receptor (MOR) in the brain, resulting in respiratory depression and eventually death3. To reverse opioid overdoses,
naloxone as shown Figure 1, an antagonist to the MOR, is used as the most common antidote, usually in the nasal
formulation so as to efficiently bypass the blood brain barrier (BBB) and exert an immediate effect1.
OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
• MW: 327.37
• logP: 1.47
• logS: -1.8
Figure 1: Structure and Physicochemical Properties of Naloxone.4
However, naloxone can be distributed away from the brain rapidly, leading to a brief period of pharmacodynamic
action, which is possibly caused by its limited BBB permeability5. Considering that opioid agonists have a longer
half-life, there is a risk of inadequate response or re-narcotization after a single dose of naloxone, especially in patients
who have taken large doses or long-acting opioid formulations6. Administration of repeated doses of naloxone may
be necessary if respiratory depression recurs7. At the same time, the price of naloxone nasal spray is high8. Other
attempts to lengthen the time for reversing opioid overdose, such as combining naloxone with other opioid antagonists,
have failed9. For all these reasons, there is a demand for more effective opioid antagonists with enhanced brain
retention ability, which corresponds to high BBB permeability.
Nevertheless, developing new drugs costs 2.6 billion dollars on average, and can take more than 10 years10. Drug
discovery for lead compounds, i.e., promising drug candidates, requires iterative organic synthesis and screening
assays, with a failure rate higher than 90%11. Recently, the increase in the amount of chemical and biomedical data
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has encouraged the use of ‘data-hungry’ machine learning algorithms such as deep learning to generate and optimize
molecules, which significantly accelerates the drug discovery process by reducing resources spent on wet-lab synthesis
and characterization of bad lead compounds12,13. By representing molecules as simplified molecular-input line-entry
system (SMILES) strings, the generation of potential drug molecules can be treated as a sequence generation problem.
With reinforcement learning (RL)14, the generation can be biased towards molecules with certain desired properties.
For example, Popova et al used RL to train a molecule generator to generate novel compound libraries with a desired
physicochemical or biological property15.
For naloxone, it targets the central nervous system (CNS). Several physicochemical factors underlie permeation
through the BBB for CNS drugs16. For instance, CNS active drugs tend to have smaller molecular weight (MW).
Molecules with MW less than 500 can undergo significant free diffusion and when MW increases from 200 to 450,
BBB permeability decreases 100-fold. Besides, CNS drugs must have sufficient lipophilicity (measured by the parti-
tion coefficient between octanol and water, logP) to cross the hydrophobic phospholipid bilayer of cell membranes.
One example of increased BBB permeability with higher logP is that heroin (logP=2.3) exhibits much higher brain
uptake than morphine (logP=0.99). Besides, solubility (measured by logS) is also an important property because
successful nasal products like naloxone nasal spray usually require the active ingredient to be highly soluble7.
The driving question, in this study, is whether there can be molecules with both sufficient opioid antagonistic effect
(i.e., a higher negative logarithm of the experimental half maximal inhibitory concentration, pIC50) and enhanced brain
retention ability (i.e., a smaller MW and a higher logP) while maintaining high solubility (i.e., a higher logS). Given
that the number of drug-like molecules is estimated to be between 1030 and 1060, routine virtual screening on existing
compound libraries can not guarantee finding molecules with multiple desired properties and exhaustive searching in
the huge chemical space can be prohibitively expensive15. Therefore, a multi-objective deep reinforcement learning
(DRL) framework is used for the discovery of better opioid antagonists.
2 Methods
2.1 A Deep Reinforcement Learning Framework
Our framework consists of three major components: 1) a generative model based on an RNN model that can generate
SMILES strings; 2) a predictive model that predicts the properties of interest for a given SMILES string; and 3) an
RL engine which biases the generative model towards generating SMILE strings with desired properties, the values of
which are predicted by the predictive model.
Inspired by Popova et al15, we first train the generative model on a large corpus (∼1.9M) of real-world compound
SMILES strings to learn the syntax of SMILES so that the generative model is able to generate valid SMILES strings.
The learned weights provide a good initialization for the generative model during the RL stage. Second, we train the
predictive model which contains a predictive sub-model for every property of interest. In this paper, we built three
sub-models for pIC50, logP and logS respectively. There is no sub-model for MW since it can be directly calculated.
With the learned predictive model and well-initialized generative model, we use an RL algorithm, REINFORCE17,
to further train the generative model in an end-to-end fashion such that the generated SMILES strings can have the
desired properties. Figure 2 depicts an overview of the DRL framework.
Reinforcement Learning. Reinforcement learning refers to the problem of learning an optimal decision-making
Generative 
Model
Predictive 
Model
• SMILES String
• pIC50• Reward 
RL Engine
• MW
• logP
• logS
Figure 2: Overview of the Deep Reinforcement Learning Framework. First, the generative model samples SMILES
strings whose properties are predicted by the predictive model; the RL engine then combines all properties of each
sampled SMILES into a reward as feedback to train the generative model to generate SMILES with desired properties.
policy to acquire the maximal amount of rewards in a sequential decision scenario14. Given the previously generated
SMILES characters st = {ci}ti=0 where c0 is the start token, the stochastic policy (i.e., the generative model) piθ(a|st)
samples the next SMILES character a as its action. Then, a reward rt+1 is provided by the reward function R(st, a)
and the state st will be updated to st+1 = {c0, · · · , ct, a}. This generation process repeats until the generative model
samples a termination token or reaches a predefined maximum length of a SMILES string. RL seeks an optimal policy
pi∗θ to maximize the expected cumulative future rewards (i.e., return)
pi∗θ = arg max
piθ∈G
Eη∼piθ
[ T∑
t=0
γtrt+1
]
, (1)
where G is the set of all candidates policies piθ, and η is a sampled roll-out (i.e., a SMILES string) of length T from
piθ. γ is the discount factor and usually γ < 1. Solving equation (1) is a difficult problem, and many algorithms have
been proposed in past decades14,17,18. Here, we use a classical RL algorithm called REINFORCE.
REINFORCE. REINFORCE belongs to a family of RL algorithms called policy gradient methods14 which estimates
the gradient of certain performance measures of a decision-making policy and inputs the gradient into a stochastic
gradient ascent algorithm to improve the policy toward higher total rewards. Formally, if Gt =
∑T
k=t γ
k−trt+1,
REINFORCE seeks to maximize
J (θ) = E [ log piθ(at|st)Gt],
where J (θ) captures the expected return under the distribution of all possible state and action sequences. Note that
in REINFORCE, the policy is probabilistic, i.e., piθ(at|st) is the probability of taking action at in state st. Hence, the
gradient of the objective function J (θ) can be written as follows
∇J (θ) = E [∇θ log piθ(at|st)Gt].
However, computing ∇J (θ) is non-trivial due to the high dimensionality of the space of possible state and action
sequences. REINFORCE addresses this problem by using Monte Carlo sampling and approximating the gradient by
∇J (θ) ≈ 1
K
K∑
i=1
Ti∑
t=0
∇θ log piθ(ait|sit)Git. (2)
At each iteration, REINFORCE samples K roll-outs {sit, ait, rit+1}Ki=1 from the current policy piθ (i.e., the generative
model), which are used to estimate∇J (θ) using Equation (2). Then, parameters of the policy piθ can be updated as
θ′ = θ + α∇J (θ), (3)
where α is the learning rate.
Due to the high variance in the sampling process, training can be unstable. To address this, a baseline reward bit is
often estimated and subtracted from Gt. Hence, the gradient becomes
∇J (θ) ≈ 1
K
K∑
i=1
Ti∑
t=0
∇θ log piθ(ait|sit)(Git − bit)
]
. (4)
Thus, REINFORCE can learn the parameters of the generative model in an end-to-end fashion by using backpropaga-
tion. During training, actions leading to higher total rewards Gt will be reinforced through increasing log piθ; while
actions resulting in lower total reward will be suppressed by decreasing log piθ.
The Multi-Objective Reward Function. RL algorithms require a properly defined reward function. In this paper,
we aim to learn a generative model that is able to generate SMILES strings with multiple desired properties: 1) smaller
MW; 2) higher logP; 3) higher logS and 4) higher pIC50. Note that we only build predictors for logP, logS and pIC50,
while MW is computed directly from the SMILES string. Therefore, we introduce a multi-objective reward function
which is a weighted sum of these properties
r(sT ) =
∑
p∈P
wprp(sT ), (5)
where P = {MW, logP, logS, pIC50}, wp is the weight assigned to each property and r(sT ) is the predicted property
value for the generated SMILES string sT . Besides, we assign a negative weight to MW to convert the minimization
task to maximization. In addition, to ensure the validity of most generated SMILES strings, we regularize the gener-
ative model by penalizing the model when it generates an invalid SMILES string, with a negative reward rp. Hence,
we define the reward function R(st, a) as follows:
R(st, a) =
 0 if t < Tr(sT ) if t = T and st is valid
rp otherwise
(6)
The reward is only provided at the T th (last) step of the generation. REINFORCE uses this reward function to learn a
customized generative model that is capable of generating valid SMILES strings with multiple desired properties.
2.2 Data Collection
In order to train the generative model, we set up a SMILES-strings corpus with 1,870,310 unique compounds, which
is retrieved from ChEMBL25 database19. Note that all SMILES strings here are canonicalized, which means that they
are uniquely mapped to compounds. To train the predictive model, we acquire logS and logP data from the litera-
ture15,20 and removed the duplicates. IC50 data against MOR (ChEMBL ID: 4354) are retrieved from ChEMBL25
database19. We only include compounds with explicit IC50 values at the same scale. If the IC50 value is low, then the
corresponding compound is highly potent against its target since only a very little amount of the compound can inhibit
the target. We take their negative logarithm to get the pIC50 dataset. A high pIC50 means that the compound has high
potency. Basic statistics for the three datasets are summarized in Table 1.
2.3 Model Architecture
The Generative Model. To accelerate the training of the generative model in the RL stage, we first train the generative
model to learn the syntactical rules for constructing SMILES strings. At each time step, the generative model takes
a current prefix string of a training instance (i.e., a SMILES string), and predicts the probability distribution of the
next character (Figure 3(a)). A cross-entropy loss is calculated at each step and parameters of the model are updated
through back propagation. By treating each step as a multi-class classification problem, we fit the generative model
to existing SMILES strings such that the model can generate valid SMILES strings. Importantly, the learned weights
later serve as a good initialization for the generative model and expedite the training in the RL stage.
The generative model is a recurrent neural network21 which is capable of generating SMILES strings. Essentially, a
SMILES string is composed of a sequence of characters s = {c1, · · · , cT } from a vocabulary V and ct ∈ V for all
t ∈ [1, T ]. To facilitate the generation process, we append a start token and a termination token to the head and tail of
s, respectively. As shown in Figure 3(b), at each time step t ∈ [0, T ], the input to the generative model is a character
ct (c0 is the start token). The generative model first uses an embedding layer to convert the categorical character ct
into an embedding vector of continuous scalars, which is then processed by a recurrent layer to update its hidden state.
Finally, a dense layer and a softmax layer are used to map the hidden state to a probability distribution of the next
Table 1: Statistics for the Datasets in the Predictive Model
Property Min Max Median Count
logP -5.1 11.3 2.0 14,152
logS -13.2 2.1 -2.6 9,981
pIC50 1.8 10.2 6.1 915
t=0 t=1 t=T-1 t=TTime step
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StackGRU
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Figure 3: The Generative Model. (a) Model architecture. (b) Illustration of the generation of a SMILES string.
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Figure 4: The Architecture of the Predictive Model.
possible character, from which we sample the next character. By repeating this process until a termination token is
sampled, the generative model generates a complete SMILES string.
The Predictive Model. The predictive model consists of multiple property predictors, each for one property of
interest. Here, we consider three properties, namely, logP, logS and pIC50. Property prediction is essentially a
regression task where we aim to map a SMILES string to a scalar value. All property predictors are RNN-based
models with the same architecture. Figure 4 illustrates the predictive model architecture. First, a SMILES string is
passes through an embedding layer, converting each character in the SMILES string into an embedding vector. Second,
the recurrent layer sequentially processes the embedding vectors and constructs a temporal feature vector for the input
SMILES string. Last, three consecutive dense layers are used to map the feature vector to a property value. The
network is trained with a mean squared error (MSE) loss.
However, a large number of training examples are often required for deep learning models, like RNN, before they
can achieve superior performance. For cases where only limited training examples are available, Support Vector
Machines22 and Random Forests23 are often more competitive. Hence, for each property, we compare three different
models: Support Vector Machines22, Random Forests23 and the proposed RNN-based model, and select the classifier
with the smallest MSE. We find Random Forest works best for pIC50 prediction; while the RNN-based model works
best for logS and logP prediction. This can be due to the fact that we only have a small number of data points (∼1k)
for pIC50. In contrast, ∼14k and ∼10k training examples are available for logP and logS, respectively.
2.4 Implementation Details.
In Equation (6), we set the penalty of invalid SMILES to rp = rˆµ − rˆσ , where rˆµ and rˆσ are the average and standard
deviation of the weighted sum of rewards (i.e., r(sT ) in Equation (5)) of the SMILES strings sampled from the
initialized generative model (prior to the RL training stage). Importantly, we empirically find that the RL algorithm is
sensitive to the rp and our setting of rp strikes a good balance between validity and desired properties. We assign an
equal weight of 0.25 to logP, logS and pIC50, and −0.25 to MW. During the RL training stage, the learning rate and
maximum length of SMILES strings are set to 10−5 and 200, respectively. The generative model is trained for 240
episodes. In each episode, we sample 200 SMILES strings with a batch size of 10.
The size of the dictionary is 58 with 56 distinct SMILES tokens plus a start token and a termination token. Each
token is embedded into a 512-dimensional vector. Traditional RNN models like GRU24 and LSTM25 are inferior in
memorizing and counting thus often fail to capture algorithmic patterns in sequences26. Meanwhile, the construction
of SMILES strings needs to follow certain algorithmic rules such as atom valence constraints and bracket opening-
closure. Thus, here we use Stack-augmented GRU (StackGRU)26 as the recurrent layer in the generative model. The
stack width, stack depth and hidden size of StackRNN are 256, 200, 512, respectively. For the predictive model, an
ordinary single-layer GRU with hidden size 512 is used as the recurrent layer. The following three dense layers have
dimension sizes 128, 32, and 1 respectively, the first two of which are followed by a ReLU layer and a batch-norm
layer27. The deep learning models are implemented with PyTorch28. RDKit29 is used for validating and visualizing
the molecules. The Random Forest model for predicting pIC50 has 100 trees and is implemented with Scikit-Learn30.
3 Results
3.1 Evaluation of the DRL Framework
GRU vs StackGRU. We first compare the GRU and StackGRU in learning the syntax of SMILES strings. Specifically,
we train two generative models (see Figure 3(a): one with GRU as the recurrent layer; the other with StackGRU) on
the training corpus, and sample 10k SMILES strings from each model. By using syntactical and chemical validity
check functions from RDKit, we calculate the percentage of syntactically and chemically valid compounds. We also
measure the novelty of generated compounds by calculating the percentage of non-overlapping compounds between
the sample and the training corpus. Furthermore, by examining the percentage of non-duplicates within the sample,
we quantify the uniqueness of the generated sample.
As can be seen from Table 2, both syntactical validity and chemical validity are relatively low when using a standard
GRU compared to the StackGRU. With StackGRU, syntactical validity increased to 87.29% and chemical validity
increased to 77.40%, which demonstrates that StackGRU is better at learning the SMILES syntax. Both novelty and
uniqueness are close to 100%, which indicates that the generative model is able to generate novel and unique SMILES
strings, and does not just memorize training examples.
Property Prediction. For the predictive model, we plot the predicted value vs true value in Figure 5. Indicated by a
high correlation coefficient, i.e., R2 and low rooted mean squared error (RMSE), the predictors for logP and logS have
high precision and accuracy. However, the sub-predictive model for pIC50 has relatively poor performance, which can
be caused by the insufficient data points in the pIC50 dataset. We also apply the predictive model to Naloxone. The
predicted values for logP and logS of Naloxone are 1.94 and -2.67, respectively, which align reasonably well with the
reported properties of Naloxone (logP=1.47 and logS=-1.8)4.
Molecule Generation. Given that our goal is to bias the generation of molecules towards higher logP, logS, pIC50
and smaller MW, we sample 10k SMILES strings after the generative model is trained using REINFORCE for 0, 80,
160 and 240 episodes, respectively.
Table 2: Performance Comparison between GRU and StackGRU
Configuration Syntactical Validity (%) Chemical Validity (%) Novelty (%) Uniqueness (%)
GRU 75.87 60.74 99.32 99.99
StackGRU 87.29 77.40 98.92 99.97
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Figure 5: Predicted Value vs True Value from the Predictive Model.
Figure 6 shows the distribution of each property value for chemically valid strings from the samples. The pIC50 of the
generated molecules are biased toward higher values, albeit not significantly. The distribution of logS is significantly
shifted to the right and the distribution of MW is also significantly shifted to the left, which means molecules with
higher logS and smaller MW are more likely to be generated over training episodes. However, generated molecules
tend to have lower logP values, indicated by the left-shifted distribution of logP. This phenomenon is probably because
logP and logS are contradictory by nature. When there are more hydrophilic groups, higher logS and lower logP are
expected and vice versa when there are more hydrophobic groups. Overall, our DRL framework is able to bias the
properties of generated molecules.
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Figure 6: Shifted Distribution of Targeted Properties during RL Training.
Table 3 summarizes the syntactical validity, chemical validity, novelty and uniqueness of the generated samples. One
major issue with RL in de novo drug design in previous studies is the reduced validity15. Here, by incorporating penalty
for invalid SMILES strings in the reward function, our DRL framework generates SMILES strings approaching 100%
validity when the training episodes increase. Besides, the novelty of the generated samples is also high. Uniqueness is
decreasing as the number of episodes goes up since as the DRL training episodes increase, the generative model tends
to converge to the distribution of a smaller number of SMILES strings with the desired properties.
3.2 Identification of Potential Lead Compounds
From the RL-trained generative model at the 160th episode, we sample 10k SMILES strings and then use the fol-
lowing criteria to filter out molecules with: 1) logP > 1.94, 2) logS > −2.67, 3) pIC50 > 6 and 4) MW < 327.37.
The reason why we choose the 160th episode is that it enables balanced performance with regard to the validity, nov-
elty, uniqueness and the ability to shift property distribution. The cutoff values used in logP, logS and MW are the
predicted/calculated values for naloxone in our DRL framework. Note that our goal is to discover molecules with
sufficient inhibitory activity against MOR and optimal logP, logS and MW values to ensure prolonged brain retention
ability. We set the cutoff value of pIC50 at 6 despite the predicted pIC50 for naloxone by our predictive model is 6.93
since pIC50 ≥ 6 corresponds to active compounds15.
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Figure 7: Novel Molecules Generated in the DRL Framework. (a) At the 160th Episode. (b) At the 0th Episode.
We filtered out six novel SMILES strings from the 10k-size sample, as the identified potential lead compounds. Fig-
ure 7 (a) shows their structures drawn by RDKit, which are simple by direct visual checking. We also calculated their
synthetic accessibility score (SAS)31. SAS can range between 1 and 10. A high SAS, usually above 6, corresponds to
Table 3: Evaluation of Generated Samples during RL Training
Episode Syntactical Validity (%) Chemical Validity (%) Novelty (%) Uniqueness (%)
0th 87.29 77.40 98.92 99.97
80th 91.92 89.60 95.58 98.50
160th 96.77 95.90 93.79 65.52
240th 99.40 99.16 96.46 21.51
high molecule complexity and increased synthesis difficulty. For the six molecules, their SAS values range from 1.40
to 3.12, indicating that our DRL framework generates highly feasible molecules.
To further demonstrate the usefulness of the DRL framework, we also sample 10k SMILES strings at the 0th episode
(i.e., without RL training) and filter with the same criteria. Three SMILES strings are filtered out. Figure 7 (b) shows
their structures and predicted properties. Despite having the expected properties, their structures are very complex
with high SAS values, which indicates that the molecules generated without RL training are much less feasible.
4 Conclusion and Discussion
Recent years have seen an increasing use of deep learning in drug discovery with the rise of the ‘big data’ era12. Linear
representations of molecules, such as the SMILES strings, are broadly used in ligand-based drug discovery studies32.
By linking molecules to end points like physicochemical properties, inhibitory activity, BBB permeability, etc, end-to-
end drug discovery and development is now becoming a reality33. For example, in 2019, Insilico Medicine succeeded
in using deep learning to design new lead compounds for discoidin domain receptor 1 (DDR1) kinase inhibitors from
scratch in just 21 days34.
In this study, we aim to discover better opioid antagonists to help to combat the opioid epidemic, where the most com-
mon antidote for opioid overdose, naloxone, has limited blood brain barrier permeability. To accelerate the discovery
for better opioid antogonists candidates, we implement a multi-objective DRL framework. The framework is able to
identify valid, novel and feasible molecules with sufficient opioid antagonistic activity and enhanced brain retention
ability.
More importantly, the proposed multi-objective DRL framework has great potential in accelerating drug discovery,
which is a multi-property optimization task per se. For instance, effective and safe drugs need to exhibit a fine-
tuned combination of pharmacokinetic and pharmacodynamic properties, such as high potency, affinity and selectivity
against the drug target as well as optimal absorption, distribution, metabolism, excretion and toxicity (ADMET)35.
Our study shows that with well-designed reward functions, the multi-objective DRL framework can be customized to
generate molecules with optimal properties from different drug development aspects.
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